The Evidence Layer for Scientific AI

 Quick Explanation Copied

 Long Explanation

What BPC-157 Is

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice, with molecular formula C₆₂H₉₈N₁₆O₂₂ and molecular weight 1419.56 g/mol; it is registered in ChEMBL (CHEMBL4297358) as a natural-protein-type molecule with synonyms Bepecin, PL-10, PL-14736 and PLD-116, and is not approved for therapeutic use (therapeutic flag false, max development phase 1.0).

What the Preclinical Evidence Shows

Across rat models, BPC-157 consistently accelerates healing: it hastened reticulin and collagen formation and granulation tissue in skin incisions, colon–colon anastomoses and sponge-induced angiogenesis (n=6/group per model), with dose- and time-dependent increases in new vascular spaces Rat wound-healing model study. In an alkali-burn rat model (58 Sprague–Dawley rats) plus HUVEC assays, BPC-157 enhanced endothelial proliferation, migration and angiogenesis via the ERK1/2 pathway Alkali-burn wound healing study (ERK1/2 mechanism). Mechanistic signals across tendon, muscle and bone models include VEGF upregulation, VEGFR2 activation and tenocyte migration via FAK–paxillin; however, all such data are preclinical with uncertain translational relevance Critical review of peptide bioregulators and WADA status.

Topical PL-14736 (BPC-157) also accelerated delayed healing dose-dependently in alloxan-hyperglycemic rats, roughly matching the approved drug becaplermin in granulation maturation (n=6/group) Hyperglycemic rat wound study (PL-14736 vs becaplermin). Rat colocutaneous fistulas closed within 2 weeks of BPC-157 (10 μg/kg or 10 ng/kg i.p.) with no recurrence over 16 months, though only 60 randomized animals and limited blinding Rat colocutaneous fistula abstract.

What Is NOT Known: The Human Evidence Gap

Only three small human studies exist (combined n≈30), reporting no adverse events, but no randomized controlled trials have been conducted for BPC-157 or GHK-Cu in wound healing or musculoskeletal repair 2026 review: clinical evidence gap for BPC-157. A PRISMA systematic review (64 studies: 52 animal, 12 early human/observational) found cytoprotective, anti-inflammatory and neuroprotective preclinical signals—e.g., reduced neuronal injury in rat cerebral ischemia and improved motor recovery after spinal cord compression—but only limited short-term human safety data and no proven efficacy Gut-brain axis PRISMA systematic review. A separate commentary in Inflammopharmacology explicitly questions the claimed gastro-protective effects given the paucity of human data Critical commentary questioning GI claims.

Safety, Regulatory and Practical Caveats

• WADA status: BPC-157 is classified as S0 (unapproved substance)—prohibited in sport; grey-market products risk contamination, impurities, endotoxins and dosing inaccuracy due to absent GMP manufacturing WADA and grey-market safety risks.
• Undetermined long-term risks: systemic VEGF stimulation raises unresolved oncogenic/immunogenic concerns; human pharmacokinetics and bioavailability are unknown Safety and pharmacokinetic uncertainties.
• Positive-result bias risk: much of the literature traces to a single research group; replication by independent labs is limited, and reviews note publication bias toward favorable preclinical findings Publication bias in preclinical literature.

Confidence: Moderate that preclinical wound-healing effects are real in rodents; low confidence in any human clinical benefit. What would change this conclusion: independently replicated, adequately powered, double-blind RCTs in humans showing functional improvement—or well-designed trials showing no effect, which would falsify the translational claims.